Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

Abstract

Long-term safety, pharmacodynamic, and efficacy data from this study support a positive benefit-risk profile for mepolizumab in children with severe asthma with an eosinophilic phenotype and were similar to data in studies in adults and adolescents.